ClinicalTrials.gg
CompletedNCT01187550Updated Feb 13, 2014Results posted

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

A Phase 4 interventional study of Recombinant human growth hormone (r-hGH) in Dwarfism, Pituitary, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Per ClinicalTrials.gov, last updated 2014-02-13.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
214
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
9th of 60
214 · median 66
Started
2007
with 2 others
Phase 4
19 of 60
none open now
Registered
36th of 60
by date
Lead sponsor
4 of 60
Merck KGaA, Darmstadt, Germany

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 9th largest by enrollment, is one of 3 that started in 2007, is one of 19 in phase 4, and was the 36th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This is an open-label, prospective, multicentric, non-comparative, non-randomized Phase IV interventional study in which subjects pre-diagnosed with Growth Hormone Deficiency (GHD) were treated for 4 weeks with Saizen to compare the response between GHD children born appropriate for gestational age (AGA) and those born small for gestation age (SGA) after 4 weeks of Saizen therapy.

Read the detailed description

The response to growth hormone (GH) treatment, short-term as well as long-term, displays considerable inter individual variability. This is particularly evident for the endpoint of paediatric GH administration, that is (i.e.) the growth response, which is pronounced in children who are affected by GHD. This is an open-label, multicentric study in which subjects pre-diagnosed with GHD were treated for 4 weeks with Saizen. Two hundred fourteen GHD evaluable pre-pubertal subjects were planned to be recruited in approximately 9 sites in China. Demographic data, medical history, tanner stage, physical examination, body weight, height, bone age measurement, body mass index, review of baseline medications and procedures and blood sampling were performed at baseline visit, end of treatment visit (week 4) and at 4 week follow-up visit.

OBJECTIVES

Primary objective:

  • To compare the response between GHD children born AGA and those born SGA after 4 weeks of Saizen therapy

Secondary Objectives:

  • To explore the contribution of selected genes to the phenotype of GHD children
  • To explore the impact of gene polymorphisms on the levels of specific serum biomarkers in GHD children after 4 weeks of Saizen therapy
  • To explore the relationships between changes in gene expression and changes in serum biomarkers after 4 weeks of Saizen therapy and the spectrum of gene polymorphisms in GHD children
03

Conditions studied

  • Dwarfism, Pituitary

Browse trials for

Keywords

  • Dwarfism, pituitary
  • Growth hormone
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with documented pre-established diagnosis of GHD with a GH peak response of \<10 microgram/liter (mcg/L) with 2 GH stimulation tests, without priming with estradiol
  • Subjects with SGA defined as birth weight and/or length at least 2 standard deviations (SDs) below the mean for gestational age
  • Subjects with prepubertal status according to Tanner
  • Subjects with pre-established history of normal thyroid function or adequate substitution for at least 3 months
  • Subjects with weight for stature within the population specific normal range (>5th and \<95th percentiles) for gender
  • Subjects with willingness and ability to comply with the protocol for the duration of the study
  • Subjects whose parents or guardians written given before any study-related procedure that was not part of the subjects normal medical care, with the understanding that the subject or parent/guardian might withdraw consent at any time without prejudice to future medical care. If the child was old enough to read and write, a separate assent form was given

Exclusion criteria

Exclusion Criteria:

  • Subjects who acquired GHD due to central nervous system tumor, trauma, infection, infiltration (documented by imaging), and history of irradiation or cranial surgery
  • Subjects with previous treatment with GH, growth hormone releasing hormone (GHRH), anabolic steroids or any treatment affecting growth
  • Subjects who had previous treatment with , except in case of topical or inhaled corticosteroid administration for atopic disease. Corticosteroids for hormonal substitution were also allowed if the condition and the treatment regimen had been stable for at least 3 months
  • Subjects with severe associated pathology affecting growth such as malnutrition, malabsorption, or bone dysplasia
  • Subjects with chronic severe kidney disease
  • Subjects with chronic severe liver disease
  • Subjects with chronic infectious disease
  • Subjects with acute or severe illness during the previous 6 months
  • Subjects with significant concomitant illness that would interfere with participation or assessment in this study
  • Subjects who had active (except non-melanomatous skin malignancies that had undergone surgical excision and/or , diagnosis and treatment to resolution)
  • Subjects with history or active idiopathic intra-cranial hypertension (benign intracranial hypertension or pseudo-tumor cerebri)
  • Subjects with diabetes mellitus type I \& II
  • Subjects with any disease
  • Subjects who had previous screening failure in this study
  • Subjects who had used an drug or participated in another clinical study within the last 3 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
214 participants (actual)

Interventions

  • Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit \[IU\]/kg body weight) per day by subcutaneous injection.

    Also known as: Saizen

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4

    Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was calculated as logarithm (log) 10 actual value of IGF-1 - log 10 (mean reference value of IGF-1) divided by log10 reference standard deviation of IGF-1.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Change From Baseline in Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels at Week 4

    Time frame: Baseline and Week 4

  2. Change From Baseline in Fasting Glucose at Week 4

    Time frame: Baseline and Week 4

  3. Change From Baseline in Fasting Insulin at Week 4

    Time frame: Baseline and Week 4

  4. Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Test at Week 4

    HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.

    Time frame: Baseline and Week 4

  5. Change From Baseline in Lipid Profile at Week 4

    Total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides levels were evaluated.

    Time frame: Baseline and Week 4

07

Results

Posted Aug 7, 2012

Participant flow

Participant flow — Overall Study
MilestoneAppropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
Started18330
Treated17530
Completed16929
Not completed141
Withdrew: Protocol violation31
Withdrew: Other30
Withdrew: Randomized but not treated80

Outcome measures

PrimaryChange From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4

Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was calculated as logarithm (log) 10 actual value of IGF-1 - log 10 (mean reference value of IGF-1) divided by log10 reference standard deviation of IGF-1.

Time frame:
Baseline and Week 4
Reported as:
Mean · nanogram/millilter (ng/mL)
Change From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4
nanogram/millilter (ng/mL)Appropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
Baseline-2.04 ± 2.341-2.22 ± 2.390
Change at Week 41.38 ± 1.3580.85 ± 1.257
Statistical analysis
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.194
SecondaryChange From Baseline in Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels at Week 4
Time frame:
Baseline and Week 4
Reported as:
Mean · microgram/mL (mcg/mL)
Change From Baseline in Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels at Week 4
microgram/mL (mcg/mL)Appropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
Baseline3.16 ± 1.3862.57 ± 1.525
Change at Week 40.58 ± 0.8690.51 ± 0.805
Statistical analysis
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.752
SecondaryChange From Baseline in Fasting Glucose at Week 4
Time frame:
Baseline and Week 4
Reported as:
Mean · millimole/liter (mmol/L)
Change From Baseline in Fasting Glucose at Week 4
millimole/liter (mmol/L)Appropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
Baseline4.83 ± 0.4714.46 ± 1.106
Change at Week 40.17 ± 0.5780.22 ± 0.886
Statistical analysis
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.710
SecondaryChange From Baseline in Fasting Insulin at Week 4
Time frame:
Baseline and Week 4
Reported as:
Mean · picomole/L (pmol/L)
Change From Baseline in Fasting Insulin at Week 4
picomole/L (pmol/L)Appropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
Baseline36.17 ± 74.57523.58 ± 14.892
Change at Week 410.08 ± 81.67412.04 ± 32.389
Statistical analysis
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.265
SecondaryChange From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Test at Week 4

HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.

Time frame:
Baseline and Week 4
Reported as:
Mean · pmol/L*mmol/L
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Test at Week 4
pmol/L*mmol/LAppropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
Baseline7.91 ± 15.6625.06 ± 3.290
Change at Week 42.96 ± 18.4582.48 ± 6.527
Statistical analysis
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.308
SecondaryChange From Baseline in Lipid Profile at Week 4

Total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides levels were evaluated.

Time frame:
Baseline and Week 4
Reported as:
Mean · mmol/L
Change From Baseline in Lipid Profile at Week 4
mmol/LAppropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
Baseline (Total Cholesterol)4.16 ± 0.7524.22 ± 0.833
Baseline (HDL-Cholesterol)1.56 ± 0.4521.59 ± 0.443
Baseline (LDL-Cholesterol)2.18 ± 0.6722.19 ± 0.709
Baseline (Triglycerides)0.99 ± 0.5271.02 ± 0.638
Change at Week 4 (Total Cholesterol)-0.28 ± 0.601-0.03 ± 0.612
Change at Week 4 (HDL-Cholesterol)-0.10 ± 0.3170.02 ± 0.329
Change at Week 4 (LDL-Cholesterol)-0.24 ± 0.5460.02 ± 0.502
Change at Week 4 (Triglycerides)0.12 ± 0.551-0.09 ± 0.831
Statistical analysis
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.078
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.033
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.041
  • Appropriate for Gestational Age (AGA) vs Small for Gestational Age (SGA) · Wilcoxon rank sum test · p = 0.091

Adverse events

Collected over Adverse Events (AEs) are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until 4 weeks post drug administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Appropriate for Gestational Age (AGA)—1/175 (0.6%)27/175 (15.4%)
Small for Gestational Age (SGA)—0/30 (0%)3/30 (10%)
Most frequent serious events
Most frequent serious events
EventAppropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
AppendicitisInfections and infestations1/1750/30
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAppropriate for Gestational Age (AGA)Small for Gestational Age (SGA)
HyperhidrosisGeneral disorders0/1751/30
PyrexiaGeneral disorders5/1751/30
AnorexiaMetabolism and nutrition disorders0/1751/30
Pain In ExtremityMusculoskeletal and connective tissue disorders1/1751/30
Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders4/1750/30
HeadacheNervous system disorders3/1750/30
Ocular HypertensionEye disorders2/1750/30
VomitingGastrointestinal disorders2/1750/30
NasopharyngitisRespiratory, thoracic and mediastinal disorders2/1750/30
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/1750/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Appropriate for Gestational Age (AGA)Small for Gestational Age (SGA)Total
Mean10.52 ± 3.8449.39 ± 4.34910.35 ± 3.931
Sex: Female, Male
Sex: Female, Male(Participants)Appropriate for Gestational Age (AGA)Small for Gestational Age (SGA)Total
Female46652
Male12924153
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Sep 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2010
First posted
Aug 24, 2010
Start
Mar 2007
Primary completionActual
Sep 2008
Completion
Apr 2009
Results first posted
Aug 7, 2012
Last update
Feb 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01187550
Collaborators
Merck Serono Co., Ltd., China
Responsible party
Sponsor
First posted
Aug 24, 2010
Start date
Mar 2007
Primary completion
Sep 2008
Completion
Apr 2009
Results posted
Aug 7, 2012
Last update
Feb 13, 2014

Study contacts

Medical Responsible
study director · Merck Serono Co., Ltd., China
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion